Published in F1000Res on September 28, 2016
Global cancer statistics. CA Cancer J Clin (2011) 185.92
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Triple negative tumours: a critical review. Histopathology (2008) 4.94
Incessant ovulation--a factor in ovarian neoplasia? Lancet (1971) 3.95
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system. Gynecol Oncol (1998) 2.50
Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res (1993) 2.07
Triple-negative breast cancer. Breast Cancer Res (2010) 1.65
Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol (2005) 1.56
Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol (2012) 1.54
HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One (2007) 1.29
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol (2008) 1.08
Overexpression of HER-2 in ovarian carcinomas. Cancer Res (2001) 1.06
Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer (2013) 0.99
The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Investig (1996) 0.92
Targeted therapies in epithelial ovarian cancer. J Oncol (2010) 0.89
The clinicopathological characteristics of 'triple-negative' epithelial ovarian cancer. J Clin Pathol (2010) 0.88
Clinicopathological analysis of ovarian tumors--a study on five years samples. Nepal Med Coll J (2010) 0.82
Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype? Asian Pac J Cancer Prev (2014) 0.82
Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the "triple-negative" tumor status to disease-free and overall survival of women with epithelial ovarian cancer. Acta Histochem (2013) 0.79